Risk-adapted prophylactic tocilizumab (Actemra) proved feasible for reducing the incidence of severe cytokine release syndrome (CRS) in pediatric acute leukemia treated with CAR T-cell therapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results